The EU's medicine watchdog recently declined to approve lecanemab and is still reviewing donanemab. These Alzheimer's treatments, approved in the US last year and developed by Biogen and Eli Lilly, ...

Annovis is at the forefront, testing buntanetap in pivotal clinical trials as a therapy for Alzheimer's and Parkinson's diseases (PD). Company has filed three new patents protecting combinations of ...

Over the past 50 years, the percentage of the Down syndrome population aged 50 and older quadrupled from about 5% to nearly 20% of the population by 2020. Alzheimer's disease prevalence is roughly six ...

Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...

We spoke to Andrew Doig, professor of biochemistry at the University of Manchester, to find out more about the evolving ...

Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision ...

One in four people are left to cope alone after a diagnosis with dementia, research has found. The study by The Alzheimer’s ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

A medical expert has expressed concern over the time it takes to diagnose dementia in Japan, which averages about 16 months ...

Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Japan’s Ministry of Health, Labour and Welfare granted new drug approvals and expanded indications for conditions like cancer, insomnia and Alzheimer’s disease (AD) Sept. 24, including Eli Lilly and ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...